Radiological Disease Activity in Secondary Progressive Multiple Sclerosis

被引:2
作者
Zohar, Daniela Noa [1 ,2 ,3 ]
Magalashvili, David [1 ]
Dreyer-Alster, Sapir [1 ,4 ]
Hoffmann, Chen [1 ,3 ,5 ]
Harari, Gil [6 ]
Dolev, Mark [1 ]
Achiron, Anat [1 ,3 ,4 ]
机构
[1] Sheba Med Ctr, Multiple Sclerosis Ctr, Ramat Gan, Israel
[2] Sheba Med Ctr, Dept Neurol, Ramat Gan, Israel
[3] Tel Aviv Univ, Sackler Sch Med, Tel Aviv, Israel
[4] Sheba Med Ctr, Arrow Project Med Res Educ, Ramat Gan, Israel
[5] Sheba Med Ctr, Radiol Dept, Ramat Gan, Israel
[6] Univ Haifa, Sch Publ Hlth, Haifa, Israel
关键词
Multiple sclerosis; Secondary progressive multiple sclerosis; MRI; Immunomodulatory treatments; Neuroinflammation;
D O I
10.1159/000527720
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction: MRI activity is less frequent among secondary progressive multiple sclerosis (SPMS) patients. In the current study, we aimed to identify SPMS patients with higher radiological disease activity (RDA) and determine their clinical characteristics. Methods: We evaluated the occurrence of RDA in SPMS patients followed at the Sheba Multiple Sclerosis Center between January 1, 2015, and December 31, 2020. All patients underwent brain and spinal cord MRI examinations as a routine follow-up unrelated to clinical disease activity. Patients were subdivided into RDA and non-RDA MRI groups based on the presence of active gadolinium-enhancing T1 lesions and/or new/enlarging T2 lesions. Demographic variables and disease-related data were compared. Results: One hundred consecutive SPMS patients, 74 females, median age of 50 years, disease duration of 19.5 years, and neurological disability by the Expanded Disability Status Scale (EDSS) score of 6.0, were included in the study. The RDA group comprised 35 patients (35%), of them 65.7% (n = 23) exhibited only brain MRI activity, 22.8% (n = 8) only spinal cord MRI activity, and 11.4% (n = 4) had both. Patients in the RDA group were diagnosed at a younger mean (SD) age of 28.2 (8.9) versus 33.7 (10.1) years and were younger with a mean (SD) age of 47.8 (9.9) versus 53.4 (10.1) years, as compared with the non-RDA group. No significant differences were found in relation to disease duration, EDSS, exposure to immunomodulatory treatments, and duration of immunomodulatory treatments. Conclusions: RDA unrelated to clinical symptomatology was more frequent in a subgroup of young SPMS patients.
引用
收藏
页码:116 / 120
页数:5
相关论文
共 28 条
[1]   Parity and disability progression in relapsing-remitting multiple sclerosis [J].
Achiron, Anat ;
Ben-David, Alon ;
Gurevich, Michael ;
Magalashvili, David ;
Menascu, Shay ;
Dolev, Mark ;
Stern, Yael ;
Ziv-Baran, Tomer .
JOURNAL OF NEUROLOGY, 2020, 267 (12) :3753-3762
[2]   Microarray analysis identifies altered regulation of nuclear receptor family members in the pre-disease state of multiple sclerosis [J].
Achiron, Anat ;
Grotto, Itamar ;
Balicer, Ran ;
Magalashvili, David ;
Feldman, Anna ;
Gurevich, Michael .
NEUROBIOLOGY OF DISEASE, 2010, 38 (02) :201-209
[3]   In vivo assessment of cervical cord damage in MS patients: a longitudinal diffusion tensor MRI study [J].
Agosta, F. ;
Absinta, M. ;
Sormani, M. P. ;
Ghezzi, A. ;
Bertolotto, A. ;
Montanari, E. ;
Comi, G. ;
Filippi, M. .
BRAIN, 2007, 130 :2211-2219
[4]   Efficacy and Safety of Intravenous Cladribine in Patients with Rapidly Evolving or Early Secondary Progressive Multiple Sclerosis [J].
Alshamrani, Foziah ;
Alnajashi, Hind ;
Almuaigel, Mohammed F. .
CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (02)
[5]   Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis [J].
Baldassari, Laura E. ;
Fox, Robert J. .
DRUGS, 2018, 78 (15) :1549-1566
[6]   Can we stop immunomodulatory treatments in secondary progressive multiple sclerosis? [J].
Bonenfant, J. ;
Bajeux, E. ;
Deburghgraeve, V. ;
Le Page, E. ;
Edan, G. ;
Kerbrat, A. .
EUROPEAN JOURNAL OF NEUROLOGY, 2017, 24 (02) :237-244
[7]  
Coret Francisco, 2018, Mult Scler J Exp Transl Clin, V4, p2055217318783347, DOI 10.1177/2055217318783347
[8]   Secondary Progressive Multiple Sclerosis New Insights [J].
Cree, Bruce A. C. ;
Arnold, Douglas L. ;
Chataway, Jeremy ;
Chitnis, Tanuja ;
Fox, Robert J. ;
Ramajo, Angela Pozo ;
Murphy, Niamh ;
Lassmann, Hans .
NEUROLOGY, 2021, 97 (08) :378-388
[9]   Ocrelizumab initiation in patients with MS A multicenter observational study [J].
Ellwardt, Erik ;
Rolfes, Leoni ;
Klein, Julia ;
Pape, Katrin ;
Ruck, Tobias ;
Wiendl, Heinz ;
Schroeter, Michael ;
Zipp, Frauke ;
Meuth, Sven G. ;
Warnke, Clemens ;
Bittner, Stefan .
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2020, 7 (04)
[10]   Progressive multiple sclerosis: latest therapeutic developments and future directions [J].
Faissner, Simon ;
Gold, Ralf .
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS, 2019, 12